Equity (Details) $ / shares in Units, $ in Thousands, vaccine_dose in Millions, shares in Millions		1 Months Ended			9 Months Ended
	Mar. 18, 2021 USD ($) vaccine_dose	May 31, 2023 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Feb. 28, 2022 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Mar. 01, 2021 $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Issuance costs					$ 355	$ 298
Convertible preferred stock, par value (in USD per share) | $ / shares					$ 0.01		$ 0.01
Series B Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Preferred stock issued					$ 1		$ 1	$ 5,000
Preferred stock, outstanding							$ 4,100
Asset impairment charges					$ 4,100
Series B Preferred Stock | Level 3 | Discount Rate
Subsidiary, Sale of Stock [Line Items]
Preferred stock, measurement input								0.15
Public Offering
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold (in shares) | shares		30.0		16.0
Price per share (in USD per share) | $ / shares		$ 0.50		$ 3.13
Proceeds from sale of stock		$ 14,800		$ 49,800
ATM Offering
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold (in shares) | shares					4.5
Proceeds from sale of stock					$ 5,600
Aggregate gross number of shares that may be issued in transaction, value			$ 160,000
Issuance costs					$ 200
COVAXIN Preferred Stock Purchase Agreement | Series B Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Agreement to sell, number of shares issued in transaction (in shares) | shares									0.1
Convertible preferred stock, par value (in USD per share) | $ / shares									$ 0.01
Agreement to sell, price per share (in USD per share) | $ / shares									$ 109.60
Advance payment amount	$ 6,000
Conversion ratio (in shares)									10
Supply agreement, number of doses | vaccine_dose	10.0